Expression and functions of the STAT3-SCLIP pathway in chronic myeloid leukemia cells

Li,Li; Zhou,De; Zheng,Yanlong; Xie,Wanzhuo

doi:10.3892/etm.2016.3768

Expression and functions of the STAT3-SCLIP pathway in chronic myeloid leukemia cells

Authors:
- Li Li
- De Zhou
- Yanlong Zheng
- Wanzhuo Xie
View Affiliations

Affiliations: The Senior Department of Hematology, The First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: October 3, 2016 https://doi.org/10.3892/etm.2016.3768
Pages: 3381-3386

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic myeloid leukemia (CML) is a blood cell cancer with increased proliferation of granulocytes. Signal transducers and activators of transcription 3 (STAT3) is an important regulator of CML. To investigate the possible downstream factors of STAT3 and gain more insight into CML‑related pathways, this study focused on the superior cervical ganglia protein 10‑like protein (SCLIP, or SCG 10‑like protein) and analyzed the functions of the STAT3‑SCLIP pathway. The effects of STAT3 phosphorylation on SCLIP expression were examined by western blotting. Specific small interfering RNA (siRNA) was then used to knockdown SCLIP in the CML cell line K562 and the expression changes of STAT3 and factors further downstream, namely Bcl‑2 and cyclin E1, were detected by RT‑qPCR. Cell viability and apoptosis were also analyzed following the knockdown of SCLIP. Results showed a positive association between the phosphorylation of STAT3 and the expression of SCLIP. Knockdown of SCLIP inhibited the viability and induced the apoptosis of K562 cells. Knockdown of SCLIP did not affect the expression of STAT3 mRNA but downregulated the mRNA levels of Bcl‑2 and cyclin E1. In conclusion, the results indicate that SCLIP is a direct downstream factor of STAT3, regulates Bcl‑2 and cyclin E1 and mediates the viability and apoptosis of CML cells. Consisting of at least these four factors, the STAT3‑SCLIP pathway might play critical roles in the regulation of CML. These data provided a more profound understanding of CML-related pathways.

View Figures

View References

1	Stein B and Smith BD: Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clinical Therapeutics. 32:804–820. 2010. View Article : Google Scholar : PubMed/NCBI
2	Chaudhary V, Sachdeva P, Karanth P and Arora R: Spontaneous hemoperitoneum in chronic myeloid leukemia: An unusual etiology. J Hematol (Brossard). 2:40–41. 2013.
3	Faderl S, Talpaz M, Estrov Z and Kantarjian HM: Chronic myelogenous leukemia: Biology and therapy. Ann Intern Med. 131:207–219. 1999. View Article : Google Scholar : PubMed/NCBI
4	Hehlmann R, Hochhaus A and Baccarani M: European LeukemiaNet: Chronic myeloid leukaemia. Lancet. 370:342–350. 2007. View Article : Google Scholar : PubMed/NCBI
5	Kabel AM and Elmaaboud MAA: Cancer: Role of nutrition, pathogenesis, diagnosis and management. World Journal of Nutrition and Health. 2:48–51. 2014.
6	Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, et al: Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of a phase 3 study. Blood. 123:2317–2324. 2014. View Article : Google Scholar : PubMed/NCBI
7	Bixby D and Talpaz M: Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 25:7–22. 2011. View Article : Google Scholar : PubMed/NCBI
8	Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A and Griffin JD: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 7:345–356. 2007. View Article : Google Scholar : PubMed/NCBI
9	Pavlů J and Apperley JF: Allogeneic stem cell transplantation for chronic myeloid leukemia. Curr Hematol Malig Rep. 8:43–51. 2013. View Article : Google Scholar : PubMed/NCBI
10	Deininger MW, Goldman JM and Melo JV: The molecular biology of chronic myeloid leukemia. Blood. 96:3343–3356. 2000.PubMed/NCBI
11	Chai SK, Nichols GL and Rothman P: Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 159:4720–4728. 1997.PubMed/NCBI
12	Zhu JF, Ll ZI, Zhang GS, Meng K, Kuang WY, Li J, Zhou XF, Ll RJ, Peng HI, Dai CW, et al: Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signalings. PLoS One. 6:e237202011. View Article : Google Scholar : PubMed/NCBI
13	Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn EJ, Yun M and Kim SH: Apoptosis induced by tanshinone IIA and cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2 signaling in chronic myeloid leukemia K562 cells. Evid Based Complement Alternat Med. 2013:8056392013. View Article : Google Scholar : PubMed/NCBI
14	Kiper HD, Kaymaz B Tezcanli, Gokbulut AA, Selvi N, Avci CB, Kosova B, Iskender G, Yandim MK, Gunduz C, Sahin F, et al: STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomed Pharmacother. 67:527–532. 2013. View Article : Google Scholar : PubMed/NCBI
15	Kaymaz BT, Cetintaş VB, Aktan C and Kosova B: MicroRNA-520a-5p displays a therapeutic effect upon chronic myelogenous leukemia cells by targeting STAT3 and enhances the anticarcinogenic role of capsaicin. Tumour Biol. 35:8733–8742. 2014. View Article : Google Scholar : PubMed/NCBI
16	Ng DC, Lim CP, Lin BH, Zhang T and Cao X: SCG10-like protein (SCLIP) is a STAT3-interacting protein involved in maintaining epithelial morphology in MCF-7 breast cancer cells. Biochem J. 425:95–105. 2009. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Zhu M, Pleasic-Williams S, Lin TH, Wunderlich DA, Cheng JB and Masferrer JL: pSTAT3: A target biomarker to study the pharmacology of the anti-IL-21R antibody ATR-107 in human whole blood. J Transl Med. 11:652013. View Article : Google Scholar : PubMed/NCBI
19	Qi J, Xia G, Huang CR, Wang JX and Zhang J: JSI-124 (Cucurbitacin I) inhibits tumor angiogenesis of human breast cancer through reduction of STAT3 phosphorylation. Am J Chin Med. 43:337–347. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Ni S, Huang B, Wang L, Zhang X and Li X, Wang H, Liu S, Hao A and Li X: Overexpression of SCLIP promotes growth and motility in glioblastoma cells. Cancer Biol Ther. 16:97–105. 2015. View Article : Google Scholar : PubMed/NCBI
21	Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
22	Zhang D, He D, Xue Y, Wang R, Wu K, Xie H, Zeng J, Wang X, Zhau HE, Chung LW, et al: PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res. 71:2193–2202. 2011. View Article : Google Scholar : PubMed/NCBI
23	Nair S, Bora-Singhal N, Perumal D and Chellappan S: Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1 genes in an ID1-dependent manner. Mol Cancer. 13:1732014. View Article : Google Scholar : PubMed/NCBI
24	Kang SW, Shin YJ, Shim YJ, Jeong SY, Park IS and Min BH: Clusterin interacts with SCLIP (SCG10-like protein) and promotes neurite outgrowth of PC12 cells. Exp Cell Res. 309:305–315. 2005. View Article : Google Scholar : PubMed/NCBI
25	van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 10:389–399. 2006. View Article : Google Scholar : PubMed/NCBI
26	Wang Y, Li M, Zang W, Ma Y, Wang N, Li P, Wang T and Zhao G: MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell Oncol (Dordr). 36:385–394. 2013. View Article : Google Scholar : PubMed/NCBI
27	Spruck CH, Won KA and Reed SI: Deregulated cyclin E induces chromosome instability. Nature. 401:297–300. 1999. View Article : Google Scholar : PubMed/NCBI
28	Gurzov EN and Izquierdo M: Cyclin E1 knockdown induces apoptosis in cancer cells. Neurol Res. 28:493–499. 2006. View Article : Google Scholar : PubMed/NCBI
29	Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E III and Zhang Y: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA. 104:16158–16163. 2007. View Article : Google Scholar : PubMed/NCBI
30	Galante JM, Mortenson MM, Bowles TL, Virudachalam S and Bold RJ: ERK/BCL-2 pathway in the resistance of pancreatic cancer to anoikis. J Surg Res. 152:18–25. 2009. View Article : Google Scholar : PubMed/NCBI
31	Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M and Sahin AA: The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res. 11:8398–8402. 2005. View Article : Google Scholar : PubMed/NCBI
32	Möröy T and Geisen C: Cyclin E. Int J Biochem Cell Biol. 36:1424–1439. 2004. View Article : Google Scholar : PubMed/NCBI